Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 3,303 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diseases of the Circulatory System Clear all
Completed Not applicable Interventional Results available

Medtronic RESOLUTE ONYX Core (2.25 mm - 4.0 mm) Clinical Study

NCT02419521
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Resolute Onyx Stent - 2.25 mm - 4.0 mm
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
La Jolla, California • Clearwater, Florida • Springfield, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 15, 2026, 1:42 AM EDT
Active, not recruiting Not applicable Interventional Results available

A Study of the ReCor Medical Paradise System in Clinical Hypertension

NCT02649426
View directory record Official record
Conditions
Hypertension, Vascular Diseases
Interventions
The Paradise® Renal Denervation Ultrasound System, Sham Procedure
Device
Lead sponsor
ReCor Medical, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 15, 2026, 1:42 AM EDT
Completed Phase 3 Interventional

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

NCT04023552
View directory record Official record
Conditions
Cardiovascular Disease and Lipoprotein(a)
Interventions
TQJ230, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
8,323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
287
States / cities
Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 136 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 15, 2026, 1:42 AM EDT
Completed Not applicable Interventional

Quantifying the Role of Sensory Systems Processing in Post-Stroke Walking Recovery

NCT04553198
View directory record Official record
Conditions
Stroke, Chronic Stroke, Walking, Difficulty, Gait, Hemiplegic
Interventions
Backward Locomotion Treadmill Training (BLTT)
Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 15, 2026, 1:42 AM EDT
Completed Phase 3 Interventional

Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment

NCT00006348
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Nausea and Vomiting, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ondansetron, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
12
States / cities
Scottsdale, Arizona • Urbana, Illinois • Des Moines, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 15, 2026, 1:42 AM EDT
Completed Not applicable Interventional Results available

Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure

NCT02130687
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hypertension
Interventions
Placebo, Sitagliptin, Aprepitant, Mixed Meal Test (MMT)
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 15, 2026, 1:42 AM EDT
Completed No phase listed Observational

DISRUPT PAD III Observational Study

NCT05881421
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Not listed
Lead sponsor
Shockwave Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
26
States / cities
Palo Alto, California • Aurora, Colorado • Loveland, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 15, 2026, 1:42 AM EDT
Terminated Phase 1 Interventional

Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma

NCT02110563
View directory record Official record
Conditions
Solid Tumors, Multiple Myeloma, Non-Hodgkins Lymphoma, Pancreatic Neuroendocrine Tumors, PNET, NHL
Interventions
DCR-MYC
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 15, 2026, 1:42 AM EDT
Completed No phase listed Observational Results available

COVID19 OutcomeS in Myeloma and the Impact of VaCcines

NCT05831787
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Patient Reported Outcomes
Other
Lead sponsor
ASH Research Collaborative
Other
Eligibility
Not listed
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 15, 2026, 1:42 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients

NCT00536575
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Sorafenib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Oct 15, 2026, 1:42 AM EDT
Completed Phase 2 Interventional Results available

Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients

NCT00995930
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Atherosclerosis, Prediabetic State
Interventions
ACZ885, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 74 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Oct 15, 2026, 1:42 AM EDT
Completed Not applicable Interventional

Pilot Study Evaluating the Toray Satake Balloon Thermal Ablation System for Treatment of Paroxysmal Atrial Fibrillation

NCT01997736
View directory record Official record
Conditions
Paroxysmal Atrial Fibrillation
Interventions
Ablation
Device
Lead sponsor
Toray Industries (America), Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Royal Oak, Michigan • New York, New York • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 15, 2026, 1:42 AM EDT
Completed Not applicable Interventional Results available

The Impact of Sharing Audio Recorded Clinic Visits on Self-management in Older Adults

NCT04344301
View directory record Official record
Conditions
Diabetes Mellitus, Hypertension
Interventions
Audio recording
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
65 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Manchester, New Hampshire • Nashville, Tennessee • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 15, 2026, 1:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

NCT00245037
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition
Interventions
therapeutic allogeneic lymphocytes, busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, Total Body Irradiation (TBI), Granulocyte colony-stimulating factor (G-CSF), Phenytoin, Methotrexate
Biological · Drug · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 15, 2026, 1:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

ACR | LAB Urine Analysis Test System Evaluation of Performance

NCT04466501
View directory record Official record
Conditions
Diabetes, Hypertension
Interventions
ACR LAB
Device
Lead sponsor
Healthy.io Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
3
States / cities
Atlanta, Georgia • Lexington, Kentucky • Garden City, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2020 · Synced Oct 15, 2026, 1:42 AM EDT
Active, not recruiting Not applicable Interventional

TTVR Early Feasibility Study

NCT04433065
View directory record Official record
Conditions
Tricuspid Regurgitation
Interventions
Intrepid™ TTVR System
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 1:42 AM EDT
Not listed Phase 1 Interventional

MYOHEART™ (Myogenesis Heart Efficiency and Regeneration Trial)

NCT00054678
View directory record Official record
Conditions
Congestive Heart Failure, Coronary Artery Disease, Myocardial Infarction
Interventions
MyoCell™, MyoCath™
Drug · Device
Lead sponsor
Bioheart, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
5
States / cities
Sunrise, Florida • Atlanta, Georgia • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2007 · Synced Oct 15, 2026, 1:42 AM EDT
Not listed No phase listed Observational

Cognitive Impairment in Atrial Fibrillation

NCT01816308
View directory record Official record
Conditions
Atrial Fibrillation, Mild Cognitive Impairment, Dementia
Interventions
Not listed
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
50 Years to 75 Years
Enrollment
888 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 15, 2026, 1:42 AM EDT
Terminated Not applicable Interventional

Safety of Platelet Transfusion in Patients on Antiplatelet Therapy With Traumatic Head Injury

NCT01810276
View directory record Official record
Conditions
Traumatic Head Injury, Intracranial Hemmorhage, Anti-platelet Therapy
Interventions
Saline, Platelets
Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 15, 2026, 1:42 AM EDT
Completed No phase listed Observational Results available

Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease

NCT05465317
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Empagliflozin, Dipeptidyl Peptidate-4 inhibitors
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
62,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 15, 2026, 1:42 AM EDT
Active, not recruiting Phase 2 Interventional

Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant

NCT04876248
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Belantamab Mafodotin, Lenalidomide
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 15, 2026, 1:42 AM EDT
Completed Not applicable Interventional Results available

Vitamin D Supplementation on Cardiovascular Risk Factors

NCT01412710
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Cholecalciferol
Drug
Lead sponsor
Florida International University
Other
Eligibility
30 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 15, 2026, 1:42 AM EDT
Completed Phase 1Phase 2 Interventional

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

NCT02649790
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS
Interventions
KPT-8602, ASTX727, Dexamethasone
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
26
States / cities
Los Angeles, California • Pasadena, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 15, 2026, 1:42 AM EDT
Completed Phase 2 Interventional Results available

An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome

NCT02117713
View directory record Official record
Conditions
Alagille Syndrome
Interventions
LUM001 (Maralixibat)
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 18 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Oct 15, 2026, 1:42 AM EDT